Schedule of Events

• Incorporating Checkpoint Inhibitors into the Perioperative Management of Locally Advanced Head and Neck Cancer
  • Robert Haddad, MD, Dana-Farber Cancer Institute, Boston [M]
• Post-operative Management of Locoregionally Advance HPV(-) Head and Neck Cancer
  • Quynh-Thu Le, MD, FASTRO, Stanford Medicine, Stanford, California [R]
• HPV Negative Head and Neck Squamous Cell Carcinoma: Lots of Scientific Progress-Limited Improvement in Clinical Outcomes
  • Jeffrey Myers, MD, PhD, MD Anderson Cancer Center, Houston [S]
• Q&A

• Role of Sentinel Node Biopsy in Cutaneous Malignancy: Current Evidence and Shared Decision Making
  • Kevin Emerick, MD, Harvard Medical School and Massachusetts Eye and Ear Infirmary, Boston [S]
• Adjuvant Immunoncology Approaches for Cutaneous Squamous Cell Carcinoma in 2026
  • Danny Rischin, MD, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia [M]
• Response-adaptive Surgery for Cutaneous Malignancies: What is the Evidence?
  • Neil Gross, MD, FACS, MD Anderson Cancer Center, Houston [S]
• Evolving Role of Radiation Therapy in Cutaneous Oncology
  • Shlomo Koyfman, MD, Cleveland Clinic, Cleveland [R]

• Musaddiq Awan, MD, Medical College of Wisconsin, Milwaukee [R]
• Julie Bauman, MD, MPH, George Washington Cancer Center, Washington, DC [M]
• Michael Moore, MD, Indiana University, Indianapolis [S]

• Pembrolizumab With ctDNA-Guided Response-Adaptive Pulsed Chemotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: The SINERGY Trial
  • Ari Rosenberg, MD, Department of Medicine, Section of Hematology and Oncology, University of Chicago, Chicago [M]
• Amivantamab Plus Pembrolizumab in Previously Untreated Recurrent/Metastatic Head and Neck Squamous Cell Cancer: Results From the Phase 1b/2 OrigAMI-4 Study
  • Ranee Mehra, MD, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore [M]
• Ficerafusp Alfa 2000 mg Q2W Plus Pembrolizumab as First-Line (1L) Treatment for HPV-Negative Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Dan Zandberg, MD, UPMC Hillman Cancer Center, Pittsburgh [M]
• Danvatirsen Plus Pembrolizumab Versus Pembrolizumab as First-Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): Final Results of a Randomized Phase 2 Trial
  • Deborah Wong, MD, PhD, Division of Hematology-Oncology, Department of Medicine, UCLA David Geffen School of Medicine, Los Angeles [M]
• Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding ROR2-Targeting ADC, in Patients With Treatment Refractory HPV+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
  • Alan Ho, MD, PhD, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York [M]
• Cholinergic CD8+ T Cells Enhance Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
  • Hannah Shapiro, BS, NYU Langone Health, New York [Research Associate]

• Integrating New Re-irradiation Paradigms into the Evolving World of Recurrent/Metastatic HNSCC
  • Nadeem Riaz, MD, MS, Memorial Sloan Kettering Cancer Center, New York [R]
• Rethinking Resectability with Modern Chemotherapy/Immunotherapy for Recurrent/Metastatic Head and Neck Cancer
  • John de Almeida, MD, Princess Margaret Cancer Centre, Toronto, Ontario, Canada [S]
• Emerging Therapeutics in Recurrent/Metastatic HPV Negative HNSCC
  • Paul Swiecicki, MD, University of Michigan, Ann Arbor, Michigan [M]
• Q&A

• Role of EBV DNA in the Treatment of Nasopharyngeal Carcinoma
  • Nancy Lee, MD, FASTRO, Memorial Sloan Kettering Cancer Center, New York [R]
• The Potential Role of HPV DNA in the Oropharyngeal Carcinoma
  • Carole Fakhry, MD, Johns Hopkins University, Baltimore [S]
• Complex Viral-Host DNA Structures in HPV-Driven Cancers
  • Keiko Akagi, PhD, MD Anderson Cancer Center, Houston [M]

• Surgical Outcomes in KEYNOTE-689: Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)
  • Richard Bell, MD, Providence Cancer Institute Frantz Head and Neck Clinic, Portland, Oregon [S]
• A Prospective Trial of Single-Dose Neoadjuvant PD-1 Blockade With or Without a CD40 Agonist in HPV-Negative HNSCC
  • Lova Sun, MD, University of Pennsylvania, Philadelphia [M]
• Postoperative Lymphatic Fluid Circulating Tumor DNA (ctDNA) in Intermediate-Risk HPV-Independent HNSCC to Identify Patients at High Risk of Recurrence
  • Zhuosheng Gu, Droplet Biosciences, Cambridge, Massachusetts [Senior Director]
• The Quarterback De-Escalation Trials: Sequential Studies of Induction Chemotherapy and Reduced Dose Chemoradiation for HPV-Positive Oropharynx Cancer
  • Michael Wotman, MD, MD Anderson Cancer Center, Houston [M]
• Early Results of a Multisite Phase II Study of ctDNA-Guided Adjuvant Radiation for Patients With HPV-Related Oropharyngeal Cancer
  • James Bates, MD, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta [R]
• Discordance Between Circulating HPV DNA and Tumor-Informed ctDNA Assays in Predicting Outcomes for De-Escalated Oropharyngeal Cancer (OPC) Patients
  • Bill Diplas, MD, PhD, Memoria, Durham, North Carolina [R]
• Safety and Efficacy of an LED-Based Intraoral Device for Daily Photobiomodulation Therapy Prior to Radiation Treatment in Reducing Severity of Oral Mucositis in Head and Neck Cancer Patients
  • Kenneth Shung Hu, MD, FASTRO, Department of Radiation Oncology, NYU Langone Health, New York [R]
• Clinical Validation of AI Contouring for Comprehensive Head and Neck Target Delineation for Radiation Treatment
  • Sharif Elguindi, MS, Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York [Medical Physicist]

• Samir Khariwala, MD, MS, University of Minnesota, Minneapolis [S]
• C. Jillian Tsai, MD, PhD, MS, Princess Margaret Cancer Center, Toronto, Ontario, Canada [R]
• Dan Zandberg, MD, UPMC Hillman Cancer Center, Pittsburgh [M]

• Management of Anaplastic Cancer in the BRAF Era
  • Ashok Jethwa, MD, University of Minnesota, Minneapolis [S]
• Considerations Around Medullary Thyroid Cancer in the GLP-1 Era
  • Kristen Otto, MD, Moffitt Cancer Center, Tampa, Florida [S]
• Ordering and Incorporating Genetic Testing into Surgical Decision Making for WDTC
  • Joseph Scharpf, MD, Cleveland Clinic Cancer Center, Cleveland [S]
• Contemporary Management of WDTC: Patient Counseling, RAI and Surveillance
  • Maria Cabanillas, MD, MD Anderson Cancer Center, Houston [Endocrinologist]
• Systemic Treatment Options and Indications in ATC
  • Francis Worden, MD, University of Michigan Health, Ann Arbor, Michigan [M]
• Q&A

Session VI: Salivary Tumor Board: An Update on Multidisciplinary Management of Salivary Cancer
Sinatra Balloom 1-8

Moderator: Michael Moore, MD, Indiana University, Indianapolis [S]

Speakers:
Patrick Ha, MD, University of California San Francisco, San Francisco [S]
Trisha Wise-Draper, MD, PhD, University of Cincinnati, Cincinnati [M]
Sue Yom, MD, PhD, UCSF Health, San Francisco [R]

• Addressing Mental Health and Suicide Risk in Patients with Head/Neck Cancer
  • Olga Slavin-Spenny, PhD, Henry Ford Health, Detroit [Psychologist]
• Building a Survivorship Clinic
  • Joanna Bodmann, MSN, NP-C, AOCNP, Cleveland Clinic Cancer Center, Cleveland [Nurse Practitioner]
  • Bridgett Harr, DNP, AOCNP, Cleveland Clinic Cancer Center, Cleveland [Radiation Oncology Nurse Practitioner]
  • Regina Kahnert, CNP, Cleveland Clinic Cancer Center, Cleveland [Head and Neck Surgical Oncology Nurse Practitioner]
• Osteoradionecrosis: Managing A Complex Long-term Toxicity
  • Michael Fritz, MD, Cleveland Clinic Cancer Center, Cleveland [S]
• Q&A

• Deep Learning for Radiation Oncology Applications in Head/Neck Cancer
  • Clifton Fuller, MD, PhD, MD Anderson Cancer Center, Houston [R]
• Artificial Intelligence for Rapid Margin Assessment
  • Maie St. John, MD, PhD, Johns Hopkins University, Baltimore [S]
• Adaptive Systemic Antineoplastic Therapies Based on Non-HPV ctDNA Dynamics
  • Ari Rosenberg, MD, University of Chicago, Chicago [M]
• Q&A

• Neoadjuvant Therapy in Sinonasal Tumors
  • Siddharth Sheth, DO, MPH, UNC Health, Chapel Hill North Carolina [M]
• Organ-Preserving Surgery for Skull Base Tumors
  • Marc Cohen, MD, MPH, Memorial Sloan Kettering Cancer Center, New York [S]
• Update on Radiotherapy Approaches in Sinonasal Malignancies
  • Nikhil Joshi, MD, Rush University, Chicago [R]
• Q&A

• Expanding the Arsenal: Novel Systematic Strategies for Head and Neck Cancer
  • Renata Ferrarotto, MD, MD Anderson Cancer Center, Houston [M]
• Immunotherapy Frontiers in HNSCC: Emerging Clinical Trials
  • R. Bryan Bell, MD, DDS, Providence Cancer Institute Franz Head and Neck Clinic, Portland, Oregon [S]
• Precision De-escalation: Tailored Therapy Trials in HNSCC
  • Jonathan Schoenfeld, MD, Dana-Farber Cancer Institute, Boston [R]
• Q&A